31 - Clinical Trials

Moderator(s)

• 

  Kassem Bourgi, MD (he/him/his)

  Assistant Professor
  Division of Infectious Disease
  Indiana University School of Medicine
  Indianapolis, IN, United States
• 

  Yeon Joo Lee, MD;MPH

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  Closter, NJ, United States

Presentations:

• 10:30 AM – 10:45 AM US ET

  Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
  

  Co-Author: Alita Miller, PhD – Entasis Therapeutics

  Presenting Author: Sarah McLeod, PhD (she/her/hers) – Innoviva Specialty Therapeutics

  Co-Author: Adam B. Shapiro, Ph.D – Entasis Therapeutics

  Co-Author: Khurram Rana, PharmD – Entasis Therapeutics

  Co-Author: David Altarac, MD, MPA – Entasis Therapeutics
• 10:45 AM – 11:00 AM US ET

  Effect of Oral Fosfomycin Compared to the Intravenous Beta Lactam/Beta-Lactamase Inhibitor or Carbapenem in Step-down Treatment of Patients with Complicated Urinary Tract Infection due to Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae: A Multicenter, Open-label, Randomized Controlled, Non-inferiority Trial.
  

  Presenting Author: Jun-won Seo, MD, PhD (he/him/his) – Chosun University Hospital

  Co-Author: Da Young Kim, MD – Chosun university Hospital

  Co-Author: Youngmin Yoon, MD – Department of Internal Medicine, College of Medicine, Chosun University

  Co-Author: Young Sang Lyu, n/a – Department of Internal Medicine, College of Medicine, Chosun University

  Co-Author: Yong Sub Na, MD, PhD – Department of Internal Medicine, College of Medicine, Chosun University

  Co-Author: Do Sik Moon, n/a – Department of Internal Medicine, College of Medicine, Chosun University

  Co-Author: Na Ra Yun, M.D., Ph.D. – Chosun university hospital

  Co-Author: Min Seok Kim, n/a – Department of Urology, Chosun university college of Medicine

  Co-Author: Jeong-Han Kim, MD – Division of Infectious Diseases, Department of Internal Medicine, Ewha Womans University, Mokdong Hospital

  Co-Author: Sang Woon Bae, MD – Division of Infectious Diseases, Department of Internal Medicine, Yeungnam University Medical Center

  Co-Author: Jian Hur, M.D., Ph.D. – Yeungnam university hospital

  Co-Author: Min Hyung Kim, M.D. / Ph.D. – Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine

  Co-Author: Yoon Soo Park, MD, PhD – Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine

  Co-Author: Heejung Kim, MD/PhD – Department of Laboratory Medicine, Yongin Severance Hospital, Yonsei University College of Medicine

  Co-Author: Hyungdon Lee, Clinical associate professor/ Master of medical science – Chuncheon Sacred heat hospital hallym University

  Co-Author: Hee-Chang Jang, MD, PhD – Chonnam National University Hospital

  Co-Author: Dong-Min Kim, MD degree – Chosun University Hospital
• 11:00 AM – 11:15 AM US ET

  The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
  

  Presenting Author: Bruce P. Burnett, PhD (he/him/his) – InflaRx GmbH, InflaRx Pharmaceuticals, Inc.

  Co-Author: Endry H.T. Lim, MD, PhD – Amsterdam UMC

  Co-Author: Alexander Vlaar, MD, PhD – Amsterdam UMC

  Co-Author: Sanne De Bruin, MD – Amsterdam UMC

  Co-Author: Matthijs Brouwer, MD, PhD – Amsterdam UMC

  Co-Author: Maria Habel, PhD – InflaRx GmbH

  Co-Author: Claus Thielert, PhD – InflaRx GmbH

  Co-Author: James Dickinson, MSc – InflaRx GmbH

  Co-Author: simon Rückinger, PhD – Metranomia Clinical Research GmbH

  Co-Author: Robert Zerbib, MSc – InflaRx GmbH

  Co-Author: Dorothee Neukirchen, PhD – InflaRx GmbH

  Co-Author: Renfeng Guo, MD – InflaRx GmbH

  Co-Author: Diederik van de Beek, MD, PhD – Amsterdam UMC

  Co-Author: Niels Riedemann, MD, PhD – InflaRx GmbH
• 11:15 AM – 11:30 AM US ET

  Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial
  

  Presenting Author: Deepa B. Gotur, MD, FCCP, FCCM (she/her/hers) – Weill Cornell Medical College and Houston Methodist Hospital

  Co-Author: Anuj Malik, MD, MS – Ascension St. John's Medical Center

  Co-Author: Vadim Markovtsov, PhD – Rigel Pharmaceuticals, Inc.

  Co-Author: Lucy Yan, MD, PhD (he/him/his) – Rigel Pharmaceuticals

  Co-Author: Wolfgang Dummer, MD, PhD – Rigel Pharmaceuticals

  Co-Author: Ziad Mallat, MD, PhD – University of Cambridge
• 11:30 AM – 11:45 AM US ET

  The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
  

  Presenting Author: Saul N. Faust, FRCPCH PhD (he/him/his) – University of Southampton and University Hospital Southampton NHS Foundation Trust

  Co-Author: Katrina Cathie, MBE, FRCPCH – University of Southampton

  Co-Author: SB Drysdale, FRCPCH, PhD – St George's, University of London

  Co-Author: S Royal, FRCGP – University of Nottingham

  Co-Author: C Felter, MD – Sanofi

  Co-Author: NC Vassilouthis, MD – Sanofi

  Co-Author: Mathieu Bangert, PhD – Sanofi Vaccines, Lyon, France

  Co-Author: K Mari, PhD – Sanofi

  Co-Author: R Nteene, MD – Sanofi

  Co-Author: M Roberts, MD – Sanofi

  Co-Author: M Knuf, MD – Klinikum Worms

  Co-Author: F Flamein, MD – CHU Lille

  Co-Author: P Tissieres, MD – APHP